The US Food and Drug Administration approved an adjuvant treatment for patients with completely resected melanoma.
A recent study found that multiple factors including insurance status, ethnicity, and individual providing the diagnosis are associated with delays in treatment for patients with melanoma.
An adjuvant combination regimen may improve the rate of relapse-free survival by 19% in patients with stage III BRAF-mutated melanoma.
Recently published long-term survival data shows the benefits of combining two conventional therapies to treat patients with advanced melanoma.
Patients with advanced melanoma who are treated with nivolumab after their first disease progression may experience tumor response without compromising safety.
Recent research compared survival outcomes of patients newly diagnosed with melanoma who received a sentinel lymph node biopsy within 30 days and those who received biopsy after 30 days.
An embedded palliative care program results in earlier and prolonged access to palliative care.
Central nervous system imaging is needed during programmed death 1 inhibitor therapy to monitor incidence, patterns of progression, and outcomes of melanoma brain metastases.
Financial toxicity and excessive financial burden appeared common among melanoma survivors, frequently leading to disease-related distress.
Stage III and IV melanoma may have a profound impact on patients’ distress burden, which requires further intervention strategies.